Moreover, Modest et al. recently reported median survival times of 23.5 months in KRAS wild-type, 18.9 months in KRAS codon 12-mutated and only 13 months in BRAF-mutated CRC patients on cetuximab-based first-line therapy[21]. The gene discussed is BRAF; the disease is colorectal carcinoma.